Lilly outdoor sign
Drug company Lilly is providing refunds for 340B overcharges on 14 NDCs during 3Q 2019.

Lilly Providing Refunds for 340B Overcharges During Q3 2019

Drug manufacturer Lilly is giving 340B covered entities refunds for overcharges on 14 NDCs during Q3 2019 after restating Medicaid average manufacturer prices and best prices “to account for lagged transactional data,” the company says on a notice on the U.S. Health Resources and Services Administration (HRSA) website.

Lilly said the price restatements resulted in both upward and downward adjustments to its 340B prices. Its notice includes a table showing nine NDCs whose 340B prices rose.  

Drug manufacturer Lilly is giving 340B covered entities refunds for overcharges on 14 NDCs during Q3 2019 after restating Medicaid average manufacturer prices and best prices “to account for lagged transactional data,” the company says on a notice on the U.S. Health Resources and Services Administration (HRSA) website.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer